Claims data analysis of 2115 ankylosing spondylitis patients without uveitis who started TNF inhibitor therapy revealed that the median time to the onset of uveitis was longest for those taking adalimumab (243 days), followed by etanercept (182 days) and infliximab (144 days).&nbsp

Between 2010 and 2013, $95 billion in branded pharmaceutical patents will have expired, leading to significantly higher sales opportunities for those manufacturing generics and biosimilars.

These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.

These abstracts and presentations were presented Thursday 11 June at the EULAR 2015 annual meeting.

EULAR 2015 started the afternoon of Wednesday June 10th.

CVD risk is significantly augmented in gout. Choi and coworkers studied this issue using a UK general population database using an incident user cohort study with propensity score matching.

While many adult rheumatologists are able to lessen or withdraw DMARD and biologic therapy in adults, little is known about the success of this practice in pediatric rheumatology clinics.

A 12-week, phase III, non-inferiority, randomized clinical trial of tofacitinib, etanercept or placebo was conducted in 1106 patients with plaque psoriasis.

Researchers from the University of Manchester investigated self-reported adherence to biologic treatment in RA and found that 41% of patients were non-adherent to adalimumab therapy at least once, and 23% were nonadherent overall. http://bit.ly/1KA2

IL-17 inhibitors are being developed for treatment of psoriasis, psoriatic arthritis and axial spondyloarthritis. Broadalumab has been in phase II & III trials and been developed by a partnership between Amgen and Astra-Zeneca.

A prospective study of sildenafil was conducted in 25 centers that included 83 patients and 192 digital ulcers at entry. The odds of healing ulcers was less, but not significant, for sildenafil.

Three phase III studies of sarilumab (SARIL-RA-TARGET, -EASY and -ASCERTAIN), a fully-human IL6 receptor antibody, have been reported and met primary end points in these pivotal clinical trials.

The manufacturers of the 2 best selling TNF inhibitors, Enbrel and Humira, have announced a 9.9% price increase of May 1st. The current average price of Enbrel is $42,000 per annum.

Carl Schoellhammerhas just won the Lemelson-MIT National Collegiate Student Prize for his invention - the microneedle pill.

The FDA has granted adalimumab (Humira) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease).

A Finnish early RA register studied 14,878 incident RA patients from 2000-2008 and identified 1157 deaths.  Patients receiving DMARDs and MTX had lower mortality rates. The standardized moratility ratio for the entire cohort was reduced (0.57, 95% CI 0.52 to 0.62).

May 10 was World Lupus Day.

According to the Federal Trade Commission biosimilars have the potential to save the U.S. healthcare system $250 billion through 2022.

Hepatic enzyme elevations with TNF inhibitor use is not uncommon.

Researchers at MD Anderson Cancer Center in Houston prospectively studied 107 RA patients with regard to oral medication (DMARDs, steroids) adherence. They report that adherence was low, ranging from 58-71% overall.